Sharps Technology Inc(STSS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -8.2 | Insider Own | 34.68% | Shs Outstand | 39.4M | Perf Week | 3.95% |
| Market Cap | 0.08B | Forward P/E | - | EPS next Y | - | Insider Trans | -5.86% | Shs Float | 27.6M | Perf Month | 2.79% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | - | Inst Own | 18.47% | Short Float | 2.16% | Perf Quarter | -4.17% |
| Income | -0.37B | P/S | 7.53 | EPS this Y | - | Inst Trans | 9.04% | Short Ratio | 1.91 | Perf Half Y | -34.98% |
| Sales | 0.01B | P/B | 0.41 | EPS next 5Y | - | ROA | -358.52% | Short Interest | 0.60M | Perf YTD | -9.36% |
| Book/sh | 4.54 | P/C | 6.12 | EPS past 3/5Y | 85.67% 63.36% | ROE | -379.39% | 52W High | -89.91% ($18.23) | Perf Year | -51.96% |
| Cash/sh | 0.3 | P/FCF | - | Sales past 3/5Y | - | ROIC | -206.73% | 52W Low | 30.04% ($1.41) | Perf 3Y | -99.97% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.5% | Gross Margin | -5.84% | Volatility(W/M) | 4.86% 5.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 6.3 | Sales Y/Y TTM | - | Oper. Margin | -1101.46% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.08 | EPS Q/Q | -103.08% | Profit Margin | -3575.77% | RSI (14) | 49.02 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.28 | Sales Q/Q | - | SMA20 | -2.06% ($1.88) | Beta | 2.03 | Target Price | $22 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/4/6 | SMA50 | 2.31% ($1.8) | Rel Volume | 1.63 | Prev Close | $1.82 |
| Employees | - | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -50.03% ($3.68) | Avg Volume(3M) | 0.31M | Price | $1.84 |
| IPO | 2022/4/14 | Option/Short | Yes/Yes | Trades | 1689 | Volume | 509,387 | Change | 1.1% |
💉 This innovative holding company has undergone a major transformation — pivoting from a medical device company with high-performance safety syringe technology into a Solana-based digital asset acceleration enterprise. While retaining its smart syringe IP, it is creating new corporate value through large-scale Solana asset holdings and staking.
Over the past 1 year, on the lower side
90% below its 1-year high.
Traded more than usual. That is 163% of its average volume.
STSS has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $753. Peers typically go for $251.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -100.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 18.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #40 of 53 in the industry
Based on market cap of $78M.
FAQ
What kind of company is STSS?
STSS belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of STSS?
The market cap of STSS is approximately $78M, ranking 4,712 within its sector.
What is the 52-week high and low for STSS?
STSS has recorded a 52-week high of $18.23 and a low of $1.41.